Halozyme Therapeutics (HALO) Amortization of Deferred Charges (2012 - 2018)
Halozyme Therapeutics (HALO) reported Amortization of Deferred Charges of -$455000.0 for Q4 2018, up 26.26% year-over-year from -$360378.7 in Q4 2017, and down 250.17% quarter-over-quarter from $303000.0 in Q3 2018.
Halozyme Therapeutics (HALO) Amortization of Deferred Charges (2012 - 2018) Analysis & Trends
Halozyme Therapeutics (HALO) has 7 years of Amortization of Deferred Charges data on file, last reported at -$455000.0 in Q4 2018.
- Amortization of Deferred Charges for Q4 2018 came in at -$455000.0, up 26.26% year-over-year; the trailing twelve-month figure through Dec 2018 was $1.5 million (down 12.27% YoY), and the FY2018 annual result was $1.5 million, down 12.27% from the prior year.
- Amortization of Deferred Charges slipped to -$455000.0 in Q4 2018 per HALO's latest filing, from $303000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $1.9 million in Q1 2016 and troughed at -$617000.0 in Q4 2017.
- A 5-year average of $535647.1 and a median of $452000.0 in 2016 frame the typical range for Amortization of Deferred Charges.
- On a YoY basis, Amortization of Deferred Charges climbed as much as 1085.11% in 2017 and fell as far as 236.5% in 2017.
- A 5-year view of Amortization of Deferred Charges shows it stood at $415000.0 in 2014, then jumped by 111.81% to $879000.0 in 2015, then sank by 48.58% to $452000.0 in 2016, then plunged by 236.5% to -$617000.0 in 2017, then gained by 26.26% to -$455000.0 in 2018.
- Business Quant data shows HALO's Amortization of Deferred Charges at -$455000.0 in Q4 2018, $303000.0 in Q3 2018, and $345000.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Halozyme Therapeutics | 8.24 Bn | 7.92 Bn | 297.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | -455,000.00 |
| Dec 31, 2018 | -455,000.00 |
| Sep 30, 2018 | 303,000.00 |
| Sep 30, 2018 | 303,000.00 |
| Jun 30, 2018 | 345,000.00 |
| Jun 30, 2018 | 345,000.00 |
| Mar 31, 2018 | 1.35 Mn |
| Mar 31, 2018 | 1.35 Mn |
| Dec 31, 2017 | -617,000.00 |
| Dec 31, 2017 | -617,000.00 |
| Sep 30, 2017 | 462,000.00 |
| Sep 30, 2017 | 462,000.00 |
| Jun 30, 2017 | 463,000.00 |
| Jun 30, 2017 | 463,000.00 |
| Mar 31, 2017 | 1.45 Mn |
| Mar 31, 2017 | 1.45 Mn |
| Dec 31, 2016 | 452,000.00 |
| Dec 31, 2016 | 452,000.00 |
| Sep 30, 2016 | 601,000.00 |
| Sep 30, 2016 | 601,000.00 |